New Delhi: The R21Matrix-M vaccine for malaria developed at the University of Oxford will be produced in India. The university said that under the agreement with the Serum Institute of India (CII), the vaccines produced in India will be first used in the African country of Ghana.
Vaccine scientists believe that this will reduce about half a million deaths in the world every year. The vaccine has been tested in the UK, Thailand, Burkina Faso, Kenya, Mali, and Tanzania. Their results will be released at the end of the year. SII CEO Adar Poonawala said, 200 million vaccines will be produced in a year.
Adjuvants Used for Novavax
Pro associated with vaccine development. It is the culmination of 30 years of research into malaria vaccines at Oxford, said Adrian Hill. He told that Novavax’s saponin-based adjuvant has been used in Matrix-M. It enhances the response of the immune system, making its effect more potent and lasting.
